Chikungunya - 3 Studies Found
| Completed |
: Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination : Chikungunya Virus Infection : 2025-08-31 : PXVX0317 vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP) 40mg, aluminum hydroxide 2% adjuvant, and formulation buffer suppl |
| COMPLETED |
: Phase 1 Study of SAR440894 vs Placebo : Chikungunya Virus Infection : 2025-08-31 : One time 60-minute IV infusion of lyophilized placebo for SAR440894 |
| COMPLETED |
: A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years : Chikungunya Virus Infection : 2025-08-31 : Single intramuscular vaccination on Day 1 with VLA1553 full dose, a lyophilized live-attenuated Chikungunya vaccine candidate |